On Friday, Shares of Baidu Inc (ADR) (NASDAQ:BIDU), lost -2.07% to $146.00.
MIT Technology Review revealed its annual list of Innovators Under 35. For over a decade, the global media company has recognized a list of exceptionally talented technologists whose work has great potential to transform the world.
Dr. Adam Coates of Baidu Research, a division of Baidu, Inc. (NASDAQ: BIDU), has been recognized on the list as a visionary for his work in the field of software.
Over the past six years, Adam has been a leading researcher and advocate in the area of deep learning, a branch of artificial intelligence. His thesis at Stanford University investigated the development of deep learning methods, particularly the success of large neural networks trained from large datasets.
Baidu, Inc. provides Internet search services in China and internationally. It offers Chinese language search platform on its Baidu.com Website that enables users to find relevant information online, counting Web pages, news, images, documents, and multimedia files through links offered on its Website; and international products and services to users in other countries.
Shares of Celgene Corporation (NASDAQ:CELG), DEclined -0.22% to $117.39, during its last trading session.
Celgene Corporation, declared that its tender offer to purchase any and all issued and outstanding shares of common stock of Receptos, Inc. at a price of $232.00 per share, net to the seller in cash, without interest and less required withholding taxes, expired at 12:00 midnight ET, at the end of the day on Monday, August 24, 2015.
The depositary for the tender offer has advised that, as of the expiration of the offer, a total of about 26,177,855 shares were validly tendered and not withdrawn in the tender offer (counting shares delivered through notices of guaranteed delivery), representing about 83% of Receptos’ outstanding shares. Celgene, through a wholly-owned partner, will accept for payment all shares that were validly tendered and not withdrawn preceding to expiration of the offer, and payment for such shares will be made promptly, in accordance with the terms of the offer.
Celgene anticipates to effect the merger in the coming days, with Receptos surviving as a wholly-owned partner of Celgene. As a consequence of the merger, each outstanding Receptos share not tendered and purchased in the offer (other than those as to which holders properly exercise dissenters rights) will be converted into the right to receive the same $232.00 per share price, without interest and less any required withholding taxes, that was paid in the tender offer. Following the merger, Receptos’ common stock will cease to be traded on the NASDAQ Global Market.
Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies to treat cancer and inflammatory diseases in the United States and Internationally.
Finally, FMC Technologies, Inc. (NYSE:FTI), ended its last trade with -2.06% loss, and closed at $33.20.
FMC Technologies, declared that John Gremp, Chairman and Chief Executive Officer, will address attendees on Wednesday, September 9, at 10:25 a.m. EDT.
FMC Technologies, Inc. provides technology solutions for the energy industry worldwide. The company operates through Subsea Technologies, Surface Technologies, and Energy Infrastructure segments.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
